Journal of clinical lipidology, Journal Year: 2023, Volume and Issue: 17(6), P. 748 - 755
Published: Oct. 4, 2023
Language: Английский
Nature Reviews Cardiology, Journal Year: 2024, Volume and Issue: 21(7), P. 487 - 497
Published: Jan. 4, 2024
Language: Английский
Citations
32
Archives of Medical Science, Journal Year: 2024, Volume and Issue: 20(1), P. 8 - 27
Published: Jan. 30, 2024
Lipoprotein(a) [Lp(a)] is made up of a low-density lipoprotein (LDL) particle and specific apolipoprotein(a). The blood concentration Lp(a) approximately 90% genetically determined, the main genetic factor determining levels size apo(a) isoform, which determined by number KIV2 domain repeats. isoform inversely proportional to Lp(a). strong independent cardiovascular risk factor. Elevated ≥ 50 mg/dl (≥ 125 nmol/l) are estimated occur in more than 1.5 billion people worldwide. However, determination performed far too rarely, including Poland, where, fact, it only since 2021 guidelines Polish Lipid Association (PoLA) five other scientific societies that measurements have begun be performed. Determination concentrations not easy due to, among things, different sizes isoforms; however, currently available certified tests make possible distinguish between with low high degree precision. In 2022, first for management patients elevated lipoprotein(a) were published European Atherosclerosis Society (EAS) American Heart (AHA). result work experts from two their aim provide clear, practical recommendations levels.
Language: Английский
Citations
19
Nature Reviews Cardiology, Journal Year: 2025, Volume and Issue: unknown
Published: Jan. 2, 2025
Language: Английский
Citations
2
Current Atherosclerosis Reports, Journal Year: 2024, Volume and Issue: 26(3), P. 75 - 82
Published: Jan. 22, 2024
Language: Английский
Citations
15
European Heart Journal Open, Journal Year: 2024, Volume and Issue: 4(3)
Published: April 26, 2024
Abstract Aims High lipoprotein(a) [Lp(a)] level has been demonstrated as an important risk factor for atherosclerotic cardiovascular diseases (ASCVD) amongst the older populations, whereas its effects in younger population remain unclear. This study evaluated associations between Lp(a) and of premature ASCVD. Method results PubMed Embase were searched related studies until 12 November 2023. Fifty-one including 100 540 participants included. Mean age patients ranged from 35.3 to 62.3 years. The proportion male 0% 100%. mean follow-up was provided five ranging 1 year 40 definition elevated varied among studies, such >30 mg/dL, >50 top tertiles, quartiles, quintiles, so on. Higher significantly associated with composite ASCVD [odds ratio (OR): 2.15, 95% confidence interval (95% CI): 1.53–3.02, P < 0.001], especially coronary artery disease (OR: 2.44, CI: 2.06–2.90, 0.001) peripheral arterial 2.56, 1.56–4.21, 0.001). association remained significant familial hypercholesterolaemia (FH) 3.11, 1.63–5.96, type 2 diabetes mellitus (T2DM) 2.23; 1.54–3.23, 0.001).Significant observed South Asians 3.71, 2.31–5.96, 0.001), Caucasians 3.17, 2.22–4.52, baseline low-density lipoprotein cholesterol (LDL-c) ≥ 2.6 mmol/L. Conclusion Elevated predicts or individual young, regardless design, gender, characteristics (community hospitalized), different definitions, various measurement approaches. Asians, Caucasians, FH patients, T2DM LDL-c
Language: Английский
Citations
6
Atherosclerosis Plus, Journal Year: 2023, Volume and Issue: 54, P. 1 - 6
Published: Sept. 9, 2023
Lipoprotein(a) [Lp(a)] and interleuking-6 (IL-6), an inflammation biomarker, have been established as distinct targets of the residual atherosclerotic cardiovascular disease (ASCVD) risk. We aimed to investigate association between them, potential clinical implications in ASCVD prevention.A literature search was conducted PubMed until December 31st, 2022, using relevant keywords.Elevated lipoprotein(a) levels constitute most common inherited lipid disorder associated with ASCVD. Although Lp(a) are mostly determined genetically by LPA gene locus, they may be altered acute conditions stress chronic inflammatory diseases. Considering its resemblance low-density lipoproteins, is involved atherosclerosis, but it also exerts oxidative, thrombotic, antifibrinolytic properties. The efficacy therapies lowering >90% currently investigated. On other hand, interleukin (IL)-1b/IL-6 pathway plays a pivotal role atherosclerosis IL-6 receptor inhibitors [IL-6(R)i] lower 16-41%, whereas ongoing trials investigating their anti-atherosclerotic effect. Lp(a)-lowering effect IL-6(R)i might attributed inhibition response elements promoter region gene.Although on inferior that available therapies, dual former both apolipoprotein (a) synthesis prove equal or even greater significance when comes outcomes. More required establish prevention elucidate interplay well significance.
Language: Английский
Citations
16
Pharmacological Research, Journal Year: 2023, Volume and Issue: 194, P. 106843 - 106843
Published: July 4, 2023
Lipoprotein(a) [Lp(a)], a distinct lipoprotein class, has become major focus for cardiovascular research. This review is written in light of the recent guideline and consensus statements on Lp(a) focuses 1) causal association between outcomes, 2) potential mechanisms by which elevated contributes to diseases, 3) metabolic insights production clearance 4) current future therapeutic approaches lower concentrations. The concentrations are under strict genetic control. There exists continuous relationship risk various endpoints atherosclerotic disease (ASCVD). One five people Caucasian population considered have increased concentrations; prevalence even higher black populations. makes factor public health relevance. Besides myocardial infarction, with aortic valve stenosis research during last decade. Genetic studies provided strong support outcomes: carriers variants associated lifelong concentration significantly more frequent patients ASCVD. triggered development drugs that can specifically concentrations: mRNA-targeting therapies such as anti-sense oligonucleotide (ASO) short interfering RNA (siRNA) opened new avenues than 95%. Ongoing Phase II III clinical trials these compounds discussed this review.
Language: Английский
Citations
14
European Heart Journal Open, Journal Year: 2023, Volume and Issue: 3(4)
Published: July 1, 2023
Language: Английский
Citations
13
Progress in Cardiovascular Diseases, Journal Year: 2023, Volume and Issue: 79, P. 28 - 36
Published: July 1, 2023
Language: Английский
Citations
12
European Journal of Clinical Investigation, Journal Year: 2023, Volume and Issue: 54(1)
Published: Sept. 15, 2023
Abstract Background Lipoprotein (a) [Lp(a)] is associated with coronary artery disease (CAD). However, the role of healthy lifestyle against risk CAD consideration high Lp(a) levels remains unclear. Methods This study examined 4512 participants who underwent serum level assessment at Kanazawa University Hospital from 2008 to March 2016. Their habits were based on four questionnaires regarding dietary pattern, exercise habits, smoking status and body weight. Logistic regression analyses performed identify association between independent levels. Results The significantly (odds ratio [OR]: 1.12, 95% confidence interval [CI]: 1.08–1.17, p = 1.3 × 10 −7 per mg/dL). Under these circumstances, score was also (OR: 1.24, CI: 1.12–1.36, 2.4 −8 ). Compared patients a favourable have <30 mg/dL, those an intermediate or unfavourable higher for 1.11, 1.02–1.20, 0.003 OR: 1.40, 1.16–1.54, 3.6 −5 , respectively). Further, favourable, ≥30 mg/dL 1.21, 1.08–1.34, 0.0014; 1.31, 1.14–1.48, 1.2 −4 ; 1.81, 1.44–2.18, 2.2 Conclusions Healthy lower regardless
Language: Английский
Citations
11